Insmed (NASDAQ:INSM) Announces Earnings Results

Insmed (NASDAQ:INSM) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08), FiscalAI reports. The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.13%. Insmed’s quarterly revenue was up 268.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.75) EPS.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI’s launch continues to materially outperform expectations: Third-quarter revenue reached $400.1 million, up 29% sequentially, and the product surpassed $1 billion in its first four full quarters. Insmed raised 2026 BRINSUPRI guidance to $1.35 billion-$1.4 billion.
• ARIKAYCE also delivered steady growth and faces a major potential market expansion. Third-quarter revenue rose 9% year over year to $124.4 million, prompting higher 2026 guidance of $460 million-$470 million; FDA priority review for a broader MAC lung disease label has a January 28, 2027 action date.
• Insmed expects to reach cash-flow positivity in 2027. The company ended the quarter with approximately $1.1 billion in cash, while management said BRINSUPRI’s growth should improve operating leverage even as investments continue across the pipeline.
• The long-term pipeline remains a significant growth driver, led by TPIP. TPIP’s four Phase 3 studies are advancing, with the PH-ILD trial more than 35% enrolled and ahead of schedule; management estimates more than $6 billion in peak sales potential, although approvals and clinical outcomes remain uncertain.
• Insmed is pursuing a large but still unquantified expansion of BRINSUPRI’s opportunity in COPD and asthma patients with undiagnosed comorbid bronchiectasis. AI diagnostic tools, imaging studies, physician education and other initiatives are underway, with initial findings expected around mid-2027; management characterized the opportunity as substantial but acknowledged that adoption will take time.

Insmed Trading Up 0.9%

Insmed stock traded up $0.99 during trading on Friday, hitting $112.58. The company’s stock had a trading volume of 5,184,267 shares, compared to its average volume of 3,693,269. The stock has a market capitalization of $24.59 billion, a price-to-earnings ratio of -39.92 and a beta of 0.83. The stock’s fifty day moving average is $112.66 and its 200 day moving average is $125.69. Insmed has a 1-year low of $90.39 and a 1-year high of $212.75. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Third-quarter revenue rose 268.4% year over year to $524.4 million, exceeding analyst expectations of approximately $500.4 million. The result was driven by BRINSUPRI revenue of $400.1 million, up 29% sequentially, while ARIKAYCE revenue reached $124.4 million. Insmed third-quarter financial results
• Positive Sentiment: Insmed raised its 2026 revenue outlook to $1.35 billion-$1.40 billion for BRINSUPRI and $460 million-$470 million for ARIKAYCE, signaling stronger-than-expected demand and execution. The company also launched BRINSUPRI in Japan. Insmed raises 2026 revenue outlook
• Positive Sentiment: Management said the U.S. BRINSUPRI launch continues to exceed expectations. Unusually heavy options activity, including call-option purchases more than twice the typical daily volume, may also be reinforcing bullish investor sentiment. Insmed Brinsupri sales report
• Negative Sentiment: Insmed reported a third-quarter loss of $0.46 per share, worse than the roughly $0.38 consensus estimate. The company remains unprofitable, so continued valuation support depends heavily on sustained BRINSUPRI growth and successful commercialization. Insmed third-quarter earnings report

Analysts Set New Price Targets

Several brokerages have recently issued reports on INSM. Bank of America restated a “buy” rating and issued a $207.00 price objective on shares of Insmed in a research report on Monday, October 12th. Stifel Nicolaus set a $195.00 price objective on Insmed in a research report on Thursday. Morgan Stanley cut their target price on shares of Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a research note on Wednesday, October 21st. Jefferies Financial Group restated a “buy” rating and issued a $175.00 target price on shares of Insmed in a report on Thursday, August 6th. Finally, Roth Capital restated a “buy” rating and issued a $198.00 target price (down from $212.00) on shares of Insmed in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $196.70.

Insider Activity

In related news, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.